AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-asparaginase
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3 g/sqm (high dose)
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 0.5 g/sqm (intermediate dose)
Study NCT00762281 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MEL 80 Hyperopic LASIK Treatment
Description: Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
Study NCT04772456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].
Study NCT02106715 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Two exercises for training of core stability and mobility.
Study NCT02928198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABSORB BVS
Study NCT00902590 — intervention group
Intervention type: OTHER
Intervention: saliva sample and questionaire
Description: Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire.
Study NCT00902590 — intervention group
Intervention type: OTHER
Intervention: saliva sample, questionaire
Description: Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
Study NCT01451177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured dermal and epidermal cells
Description: A piece of occipital scalp, plucked of hairs prior to excision, is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. The cells are then injected into the balding area of the scalp of the original subject.
Study NCT02643121 — intervention group
Intervention type: OTHER
Intervention: therapy sepsis
Description: Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
Study NCT03028324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
Study NCT01560806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Commune Hypertension Management
Description: People with high blood pressure will be invited to join the management programme, with monthly check-up, delivery of multi anti-hypertensive drugs and lifestyle consultation.~Antihypertensive drugs delivered to local patients included (1) low-dose hypothiazide diuresis, (2) calcium channel blocker and (3) ACEI
Study NCT03534817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Access CR
Description: Participants in the Early Access CR group will begin CR within 1-week post-hospital discharge following their MI, as opposed to Standard Access CR group which begins 7-weeks post-hospital discharge, and the Canadian average (10-14 weeks post-hospital discharge). No further intervention or differentiation between groups is applied; the actual CR program is standardized between groups, and follows the guidelines regularly practiced by the institution.
Study NCT00914940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.
Study NCT00914940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.~For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.~In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules.
Study NCT00914940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).
Study NCT00914940 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation (TBI)
Description: TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).
Study NCT00914940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Affinity Cell Sorting
Description: Device
Study NCT00914940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Patient will undergo a PBSC transplantation
Study NCT00914940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation
Study NCT00914940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Description: Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
Study NCT01197846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: quetiapine 300 mg or 600 mg
Study NCT01197846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00234533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin (rDNA origin)
Description: Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
Study NCT03784677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPV6 Calcium Channel Inhibitor SOR-C13
Description: Given IV
Study NCT01712802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Denture Adhesives: Cream
Description: Using Polident as denture adhesive to compare its effect on PRO and subjective outcomes.
Study NCT01712802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Denture Adhesives: Powder
Description: Using Poligrip powder as denture adhesive to compare its effect on PRO and subjective outcomes.
Study NCT01712802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: work as control for Denture Adhesives: Cream and Powder
Study NCT01824355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ninja 3 PLUS Investigational BG Monitoring System
Description: Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
Study NCT02097030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filcon II 3
Description: Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Inj tramadol 50 mg IV will be given on SOS basis in ward.
Study NCT02531048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 laser stimulations for each site on the upper limbs
Description: 20 laser stimulations for each site : back of the hands and arms front face
Study NCT02531048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser stimulations on face and neck
Description: 15 lasers stimulations for each site : mandibular areas and areas below the ears.
Study NCT03119402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Reading Training
Description: RRT is a computerized reading training program designed for Italian students with dyslexia. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
Study NCT03119402 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Rhythmic Reading Training
Description: RRT is a computerized reading training program designed for Italian students with dyslexia. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
Study NCT03119402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS (transcranial direct current stimulation) is a noninvasive weak-current brain stimulation technique that can facilitate (anodal electrode) or inhibit (cathodal electrode) cortical activity, thus offering exciting possibilities for the enhancement and treatment of impaired cognitive abilities.
Study NCT03119402 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS (transcranial direct current stimulation) is a noninvasive weak-current brain stimulation technique that can facilitate (anodal electrode) or inhibit (cathodal electrode) cortical activity, thus offering exciting possibilities for the enhancement and treatment of impaired cognitive abilities.
Study NCT00054457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00101296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT00101296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00101296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03371849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast and levocetirizine FDC
Description: HCP1102
Study NCT00054457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT02986529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GV-971
Study NCT02986529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971
Study NCT02986529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT04305743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA 100 UNT
Description: Intradetrusor onabotulinumtoxin A is administered cystoscopically with 100 unit dose given as either 5 or 20 injections in a single procedure based on the arm the participant is randomized into.
Study NCT03371849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair + xyzal
Description: HGP0813 + HGP1408
Study NCT02272608 — intervention group
Intervention type: OTHER
Intervention: Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio
Description: CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
Study NCT01345253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: 10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
Study NCT01345253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
Study NCT03701022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.
Study NCT01309802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinum toxin type-A
Description: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
Study NCT01560962 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: povidone iodine
Description: over the counter (OTC) 5% povidone iodine (PI)
Study NCT01560962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Study NCT01560962 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Study NCT01560962 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tobramycin-dexmethasone
Study NCT01560962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: warm soaked eyelid wash
Study NCT04305743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 UNT
Description: Intradetrusor onabotulinumtoxin A is administered cystoscopically with 100 unit dose given as either 5 or 20 injections in a single procedure based on the arm the participant is randomized into.
Study NCT02097030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
Study NCT02097030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
Study NCT04779047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.
Study NCT04779047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.
Study NCT04779047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab 800 mg once.
Study NCT04779047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ Ritonavir
Description: Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
Study NCT04779047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Ivermectin 36 mg at day 1,3 and 6.
Study NCT00110422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.
Study NCT00110422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.
Study NCT02962609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semielevated Side-lying Position-ESL
Description: The infants in the experimental group (n = 38) were held in the ESL position. In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infantswere held in the side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and their head and neck were held at the same level by the researcher; whereas, their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
Study NCT02962609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semielevated Supine Position
Description: The ESU position was applied to the infants in the control group (n=42). In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and they was laid in the supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
Study NCT00542633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject™
Description: Dosage as individually required
Study NCT00542633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Human Insulin
Description: Dosage as individually required
Study NCT01558960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVit Melphalan
Description: IVit injections of Melphalan
Study NCT00267956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1275 63 mg
Description: The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
Study NCT00267956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CNTO 1275 63 mg
Description: The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
Study NCT00267956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
Study NCT00267956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
Study NCT01262794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection, single dose
Study NCT01262794 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection Single-dose
Study NCT01495754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coffee
Description: Comparison of different amounts of coffee